Clinical trials: Dose Administration Aids
Children With Confirmed HIV Infection, Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose
Dosing, Safety and Pharmacokinetic Profile of Rifabutin in Children Receiving Concomitant Treatment With Kaletra
Open label pharmacokinetic RBT dose-finding study in young (≤ 5 year old) HIV-infected children receiving a LPV/RTV-based ART regimen and who have a recent history of completing TB treatment.
- Conditions
- Children With Confirmed HIV Infection, Receiving ART Regimen Containing 2 NRTIs + LPV/RTV at Standard Dose, Successfully Completed TB Treatment in the Past 2 to 6 Weeks of Enrollment
- Trial name
- RBT (NCT01259219)
- Testing
- Mycobutin
- Where
- 3 sites in South Africa
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Harriet Shezi Children's Clinic
Human Immunodeficiency Virus
First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LS
This first clinical study of 10-1074-LS will evaluate its safety, tolerability and pharmacokinetics profile when administered alone or in combination with 3BNC117-LS to HIV (human immunodeficiency virus) -infected and…
- Trial name
- NCT03554408
- Testing
- 10-1074-LS, 3BNC117-LS
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
HIV Infections
A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIV
The study aims to evaluate the safety, tolerability and pharmacokinetic (PK) properties of a single dose of VH5356136 in adult participants without human immunodeficiency virus (HIV).
- Trial name
- NCT07822477
- Testing
- VH5356136 Formulation 1, VH5356136 Formulation 2
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infection
Study of Single IV Administration of P2G12
A randomised phase I trial of a monoclonal antibody which neutralises HIV-1 (P2G12) to be given as a single intravenous infusion to healthy human volunteers to assess the safety and reactogenicity
- Trial name
- FuturePharma (NCT02923999)
- Testing
- P2G12 Dose Cohort 1, P2G12 Dose Cohort 2, P2G12 Dose Cohort 3
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
HIV Prevention
ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study
The purpose of this study is describe the safety and single-dose pharmacokinetics of rectally-administered IQP (ImQuest Pharmaceuticals)-0528 (DuoGel) in plasma, rectal tissue biopsies, vaginal tissue biopsies, rectal fluid and…
- Trial name
- NCT03082690
- Testing
- DuoGel
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Human Immunodeficiency Virus
A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects
The purpose of this study is to assess the safety and tolerability of intravaginal administration of P2G12. 11 subjects will receive P2G12/placebo. Three subjects in Group 1 will receive up to 7mg of P2G12, or placebo.
- Trial name
- NCT01403792
- Testing
- P2G12
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Infection, Human Immunodeficiency Virus
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects
LAI115428 is a Phase I, randomized, repeat dose escalation study to determine the safety, tolerability, and PK profile of intramuscular and subcutaneous injections of GSK1265744 in a long acting parenteral (LAP) formulation in…
- Trial name
- NCT01593046
- Testing
- GSK1265744 Oral, GSK1265744 LAP 800mg intramuscular injection, GSK1265744 LAP 200mg subcutaneous injection
- Where
- 2 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Single Dose Pharmacokinetics of Oral Dextran Sulfate (UA001) and Intravenous Dextran Sulfate in Healthy Volunteers
To evaluate how the drug dextran sulfate (DS) is absorbed by the stomach and intestines when taken by mouth. To evaluate its effect on blood coagulation. DS has been reported to have anti-HIV activity.
- Trial name
- NCT00000690
- Testing
- Dextran sulfate
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Bioequivalency Study of Zidovudine Under Fasting Conditions
The objective of this study was to assess the bioequivalence of Roxane's zidovudine 300 mg tablet compared to GlaxoSmithKline's Retrovir® 300 mg tablet under fasting conditions using a single-dose, randomized, 2-treatment…
- Trial name
- NCT00602550
- Testing
- Zidovudine
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Healthy
Vaccine Treatment for HIV-Infection
This study will determine the safety and side effects of an experimental adenoviral vector vaccine given to patients who previously received a different HIV vaccine (VRC-HIVDNA016-00-VP) in a prior NIAID study.
- Trial name
- NCT00108654
- Testing
- VRC-HIVADV014-00-VP
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immune Deficiency Syndrome, Human Immunodeficiency Virus
Dose Optimisation of Stavudine for the Treatment of HIV Infection
The purpose of this study is to demonstrate whether low dose stavudine (d4T) is non-inferior (in terms of both viral suppression and toxicity) to tenofovir (TDF) after 2 years of HIV treatment.
- Trial name
- D4T (NCT02670772)
- Testing
- Stavudine, Tenofovir Disoproxil Fumarate
- Where
- 3 sites in India, South Africa and 1 more
- Volunteers
- 1,077 people, healthy volunteers welcome
- Sponsor
- Willem Daniel Francois Venter
HIV Infections
Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults
This study will test the safety of and immune system response to a new HIV vaccine. The vaccine in this study is made from HIV DNA produced in a laboratory.
- Trial name
- NCT00069030
- Testing
- VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP
- Where
- 7 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, HIV Seronegativity
A Study of GENEVAX-HIV, a Possible Vaccine
The purpose of this study is to see if it is safe to give GENEVAX-HIV, a potential HIV vaccine, to HIV-negative volunteers. The study also compares the effects of GENEVAX-HIV injected into the muscle to the effects of the drug…
- Trial name
- NCT00002232
- Testing
- APL 400-003
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth-Lederle Vaccines
Acquired Immunodeficiency Syndrome
Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.
The purpose of this study is to assess the pharmacokinetics of plasma lopinavir/ritonavir over a 12-hour dosing interval, following administration to male and female HIV-negative healthy volunteers of: 1.
- Trial name
- ENCORE3 (NCT00985543)
- Testing
- lopinavir/ritonavir
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
HIV Infections
Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally
The purpose of this study is to evaluate the safety and pharmacokinetics of rectal administration of a tenofovir alafenamide (TAF)/elvitegravir (EVG) insert at two dose levels in HIV-uninfected individuals.
- Trial name
- NCT04047420
- Testing
- TAF/EVG Insert
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Pharmacokinetics of Lamivudine at Two Different Doses
The purpose of the study is to measure the pharmacokinetics (how a drug is absorbed, distributed and eliminated from the body) of lamivudine (3TC) and its active component after 3TC is given at two different doses, 300mg and…
- Trial name
- ENCORE2 (NCT00985647)
- Testing
- Lamivudine (3TC)
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
HIV Infections, Cardiovascular Disease
Effect of Rosuvastatin on Endothelial Function
Rosuvastatin belongs to a class of medications commonly called "statins" which are medications given for high low density lipoprotein (LDL) 'bad' cholesterol to prevent atherosclerosis (hardening of blood vessels) and lower risk…
- Trial name
- NCT00986999
- Testing
- rosuvastatin
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- University of Hawaii
HIV Infection, Infection, Human Immunodeficiency Virus
A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.
This study is a two-part study. Part one is designed to see how different formulations of GSK364735 are absorbed in the body and To see how food affects how GSK364735 is absorbed in the body.
- Trial name
- NCT00386347
- Testing
- GSK364735 oral solution and oral tablets
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV (Human Immunodeficiency Virus)
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects
A randomized, placebo-controlled, single-administration, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of LP-98 injection in healthy subjects in a first-in-human clinical study
- Trial name
- NCT05933824
- Testing
- LP-98 injection
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Shanxi Kangbao Biological Product Co., Ltd.
Medication Adherence, HIV Prevention
Single Dose Truvada Study
This study examines tenofovir (TFV) drug concentrations in adults one day after taking a single dose of Truvada® - a pill used to prevent and treat HIV infection.
- Trial name
- NCT03719053
- Testing
- Tenofovir
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University